A randomized trial to investigate the efficacy and safety of insulin glargine in hyperglycemic acute stroke patients receiving intensive care

Abstract This pilot, randomized, open-label controlled study compared the basal–bolus regimens of insulin glargine (IG) and neutral protamine Hagedorn (NPH) insulin in stroke patients with hyperglycemia receiving intensive care. The study recruited acute stroke patients requiring intensive care with...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sung-Chun Tang, Shyang-Rong Shih, Shin-Yi Lin, Chih-Hao Chen, Shin-Joe Yeh, Li-Kai Tsai, Wei-Shiung Yang, Jiann-Shing Jeng
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/c49257a3ce804cdc8125f9e6e2841a90
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c49257a3ce804cdc8125f9e6e2841a90
record_format	dspace
spelling	oai:doaj.org-article:c49257a3ce804cdc8125f9e6e2841a902021-12-02T15:57:11ZA randomized trial to investigate the efficacy and safety of insulin glargine in hyperglycemic acute stroke patients receiving intensive care10.1038/s41598-021-91036-22045-2322https://doaj.org/article/c49257a3ce804cdc8125f9e6e2841a902021-06-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-91036-2https://doaj.org/toc/2045-2322Abstract This pilot, randomized, open-label controlled study compared the basal–bolus regimens of insulin glargine (IG) and neutral protamine Hagedorn (NPH) insulin in stroke patients with hyperglycemia receiving intensive care. The study recruited acute stroke patients requiring intensive care within 72 h (h) of onset and had blood glucose > 200 mg/dL. 50 patients received IG (n = 26) or NPH (n = 24) with added short-acting prandial regular insulin over a 72-h period. The primary end point was the percentage of glucose within 80–180 mg/dL assessed through continuous glucose monitoring. The baseline characteristics were comparable, except the IG had higher glucose pre-randomization than the NPH (290.69 ± 82.31 vs. 246.04 ± 41.76 mg/dL, P = 0.021). The percentage of time with glucose between 80 and 180 mg/dL was 45.88 ± 27.04% in the IG and 53.56 ± 22.89% in the NPH (P = 0.341) and the percentage of glucose reduction was 31.47 ± 17.52% in the IG and 27.28 ± 14.56% in the NPH (P = 0.374). The percentage of time with glucose < 60 mg/dL was 0.14 ± 0.49% in the IG and 0.47 ± 1.74% in the NPH. Poststroke outcomes were not significantly different. In conclusion, IG is safe and equally effective as an NPH-based basal-bolus regimen for acute stroke patients with hyperglycemia receiving intensive care. Trial registration ClinicalTrials.gov, NCT02607943. Registered 18/11/2015, https://clinicaltrials.gov/ct2/show/NCT02607943 .Sung-Chun TangShyang-Rong ShihShin-Yi LinChih-Hao ChenShin-Joe YehLi-Kai TsaiWei-Shiung YangJiann-Shing JengNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-8 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Sung-Chun Tang Shyang-Rong Shih Shin-Yi Lin Chih-Hao Chen Shin-Joe Yeh Li-Kai Tsai Wei-Shiung Yang Jiann-Shing Jeng A randomized trial to investigate the efficacy and safety of insulin glargine in hyperglycemic acute stroke patients receiving intensive care
description	Abstract This pilot, randomized, open-label controlled study compared the basal–bolus regimens of insulin glargine (IG) and neutral protamine Hagedorn (NPH) insulin in stroke patients with hyperglycemia receiving intensive care. The study recruited acute stroke patients requiring intensive care within 72 h (h) of onset and had blood glucose > 200 mg/dL. 50 patients received IG (n = 26) or NPH (n = 24) with added short-acting prandial regular insulin over a 72-h period. The primary end point was the percentage of glucose within 80–180 mg/dL assessed through continuous glucose monitoring. The baseline characteristics were comparable, except the IG had higher glucose pre-randomization than the NPH (290.69 ± 82.31 vs. 246.04 ± 41.76 mg/dL, P = 0.021). The percentage of time with glucose between 80 and 180 mg/dL was 45.88 ± 27.04% in the IG and 53.56 ± 22.89% in the NPH (P = 0.341) and the percentage of glucose reduction was 31.47 ± 17.52% in the IG and 27.28 ± 14.56% in the NPH (P = 0.374). The percentage of time with glucose < 60 mg/dL was 0.14 ± 0.49% in the IG and 0.47 ± 1.74% in the NPH. Poststroke outcomes were not significantly different. In conclusion, IG is safe and equally effective as an NPH-based basal-bolus regimen for acute stroke patients with hyperglycemia receiving intensive care. Trial registration ClinicalTrials.gov, NCT02607943. Registered 18/11/2015, https://clinicaltrials.gov/ct2/show/NCT02607943 .
format	article
author	Sung-Chun Tang Shyang-Rong Shih Shin-Yi Lin Chih-Hao Chen Shin-Joe Yeh Li-Kai Tsai Wei-Shiung Yang Jiann-Shing Jeng
author_facet	Sung-Chun Tang Shyang-Rong Shih Shin-Yi Lin Chih-Hao Chen Shin-Joe Yeh Li-Kai Tsai Wei-Shiung Yang Jiann-Shing Jeng
author_sort	Sung-Chun Tang
title	A randomized trial to investigate the efficacy and safety of insulin glargine in hyperglycemic acute stroke patients receiving intensive care
title_short	A randomized trial to investigate the efficacy and safety of insulin glargine in hyperglycemic acute stroke patients receiving intensive care
title_full	A randomized trial to investigate the efficacy and safety of insulin glargine in hyperglycemic acute stroke patients receiving intensive care
title_fullStr	A randomized trial to investigate the efficacy and safety of insulin glargine in hyperglycemic acute stroke patients receiving intensive care
title_full_unstemmed	A randomized trial to investigate the efficacy and safety of insulin glargine in hyperglycemic acute stroke patients receiving intensive care
title_sort	randomized trial to investigate the efficacy and safety of insulin glargine in hyperglycemic acute stroke patients receiving intensive care
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/c49257a3ce804cdc8125f9e6e2841a90
work_keys_str_mv	AT sungchuntang arandomizedtrialtoinvestigatetheefficacyandsafetyofinsulinglargineinhyperglycemicacutestrokepatientsreceivingintensivecare AT shyangrongshih arandomizedtrialtoinvestigatetheefficacyandsafetyofinsulinglargineinhyperglycemicacutestrokepatientsreceivingintensivecare AT shinyilin arandomizedtrialtoinvestigatetheefficacyandsafetyofinsulinglargineinhyperglycemicacutestrokepatientsreceivingintensivecare AT chihhaochen arandomizedtrialtoinvestigatetheefficacyandsafetyofinsulinglargineinhyperglycemicacutestrokepatientsreceivingintensivecare AT shinjoeyeh arandomizedtrialtoinvestigatetheefficacyandsafetyofinsulinglargineinhyperglycemicacutestrokepatientsreceivingintensivecare AT likaitsai arandomizedtrialtoinvestigatetheefficacyandsafetyofinsulinglargineinhyperglycemicacutestrokepatientsreceivingintensivecare AT weishiungyang arandomizedtrialtoinvestigatetheefficacyandsafetyofinsulinglargineinhyperglycemicacutestrokepatientsreceivingintensivecare AT jiannshingjeng arandomizedtrialtoinvestigatetheefficacyandsafetyofinsulinglargineinhyperglycemicacutestrokepatientsreceivingintensivecare AT sungchuntang randomizedtrialtoinvestigatetheefficacyandsafetyofinsulinglargineinhyperglycemicacutestrokepatientsreceivingintensivecare AT shyangrongshih randomizedtrialtoinvestigatetheefficacyandsafetyofinsulinglargineinhyperglycemicacutestrokepatientsreceivingintensivecare AT shinyilin randomizedtrialtoinvestigatetheefficacyandsafetyofinsulinglargineinhyperglycemicacutestrokepatientsreceivingintensivecare AT chihhaochen randomizedtrialtoinvestigatetheefficacyandsafetyofinsulinglargineinhyperglycemicacutestrokepatientsreceivingintensivecare AT shinjoeyeh randomizedtrialtoinvestigatetheefficacyandsafetyofinsulinglargineinhyperglycemicacutestrokepatientsreceivingintensivecare AT likaitsai randomizedtrialtoinvestigatetheefficacyandsafetyofinsulinglargineinhyperglycemicacutestrokepatientsreceivingintensivecare AT weishiungyang randomizedtrialtoinvestigatetheefficacyandsafetyofinsulinglargineinhyperglycemicacutestrokepatientsreceivingintensivecare AT jiannshingjeng randomizedtrialtoinvestigatetheefficacyandsafetyofinsulinglargineinhyperglycemicacutestrokepatientsreceivingintensivecare
_version_	1718385354915971072

A randomized trial to investigate the efficacy and safety of insulin glargine in hyperglycemic acute stroke patients receiving intensive care

Ejemplares similares